Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-J591 and Ketoconazole in High-Risk Castrate Biochemically Relapsed Prostate Cancer
NCT00859781Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2009
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of 177lu-rosopatamab in prostate cancer (PCa), sponsored by Weill Cornell Medicine. Started Jun 2009; status: active, not recruiting.
02
Drugs
177lu-rosopatamab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00859781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00859781.